Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 in Thyroid Eye Disease (Extension Study)
NCT06126783Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sycume in thyroid eye disease (TED), sponsored by Innovent Biologics. Started Oct 2023; status: completed.
02
Drugs
sycume
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06126783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126783.